CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in geriatric population and rise in awareness regarding fibrin sealants
3.4.1.2. Growth in the prevalence of chronic diseases and rise in the number of surgical procedures conducted globally
3.4.2. Restraints
3.4.2.1. High cost of fibrin sealants and availability of alternate products
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging countries
CHAPTER 4: FIBRIN SEALANTS MARKET, BY DOSAGE FORMS
4.1. Overview
4.1.1. Market size and forecast
4.2. Liquid
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Liquid Fibrin Sealants Market by Liquid Type
4.3. Patch
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Powder
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: FIBRIN SEALANTS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. General Surgery
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cardiovascular Surgery
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Wound Management
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Orthopedic Surgery
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Urological Surgeries
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Ophthalmic Surgeries
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
5.8. Others
5.8.1. Key market trends, growth factors and opportunities
5.8.2. Market size and forecast, by region
5.8.3. Market share analysis by country
CHAPTER 6: FIBRIN SEALANTS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Ambulatory Surgical Centers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Clinics
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: FIBRIN SEALANTS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Dosage Forms
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Dosage Forms
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Dosage Forms
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Dosage Forms
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Dosage Forms
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Dosage Forms
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Dosage Forms
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Dosage Forms
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Dosage Forms
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Dosage Forms
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Dosage Forms
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Dosage Forms
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Dosage Forms
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Dosage Forms
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Dosage Forms
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Dosage Forms
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Dosage Forms
7.4.5.5.2. Market size and forecast, by Application
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Dosage Forms
7.4.5.6.2. Market size and forecast, by Application
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Dosage Forms
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Dosage Forms
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. South Africa
7.5.5.2.1. Market size and forecast, by Dosage Forms
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. Saudi Arabia
7.5.5.3.1. Market size and forecast, by Dosage Forms
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Dosage Forms
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Baxter International Inc.
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Becton, Dickinson and Company
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Corza Medical
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Key strategic moves and developments
9.4. CSL Behring
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Grifols, S.A.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Hemarus Therapeutics Ltd.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. Johnson and Johnson
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Nordson Corporation (Nordson Medical)
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Shanghai Raas Blood Products Co. Ltd
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Vivostat A/S
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
| ※参考情報 フィブリンシーラントは、外科手術や創傷治癒において出血を止めたり、組織を接着したりするために使用される医療材料の一種です。主成分はフィブリンというタンパク質で、体内で自然に血液の凝固過程に関与しています。フィブリンシーラントは、外科的手技において迅速な止血を可能にし、術後の合併症を減少させる効果が期待されています。 フィブリンシーラントの種類には、主に二つのタイプがあります。一つ目は、天然フィブリンシーラントで、血液凝固因子から抽出されたフィブリンとトロンビンから構成されています。このタイプは一般に、血液製剤から生成され、安全性が高く、多くの手術で使用されています。二つ目は、合成フィブリンシーラントで、化学的に合成された成分を使用しており、特定の用途においてより効率的に効果を発揮することができます。 フィブリンシーラントには多様な用途があります。主に外科手術において出血を制御する目的で使用されますが、整形外科手術や心臓手術、神経外科手術、産婦人科など、多岐にわたる分野で活用されています。特に、重大な出血が予測される場面では、フィブリンシーラントの迅速な適用が求められます。また、組織の接着剤としても機能し、骨移植や組織再生に寄与することもあります。 フィブリンシーラントの利点は、その安全性と有効性だけでなく、使用が簡便であることです。通常、使用する際には、フィブリンとトロンビンの二つの成分を混合することでフィブリンが迅速に生成され、使用箇所で凝固が進みます。この過程は生理的であり、体内に異物反応を引き起こすリスクを低減します。 現在、フィブリンシーラントに関連する技術も進化しています。ナノテクノロジーを用いた新しいフィブリンシーラントの開発が進められ、より強固な接着力や止血効果の向上が期待されています。また、バイオマテリアル技術を駆使した補助的な材料や、デリバリーシステムの研究も活発に行われており、フィブリンシーラントの機能を拡張させています。 さらに、近年の研究では、フィブリンシーラントが免疫応答に与える影響や、細胞の活性化に関する知見が進展しています。これにより、フィブリンシーラントは単なる止血剤や接着剤としてではなく、組織再生や再生医療における新たなツールとしての可能性を秘めていることが示されています。 具体的な製品としては、タイガーフィブリンなどの商業化された製品があります。これらは、手術の種類や流れに応じて適切に選択され、使用されます。フィブリンシーラントは、外科医の手技と組み合わせることでさらに効果を高めることが可能であり、今後の医療環境においてますます重要な役割を果たすと考えられています。これにより、患者に対する手術や治療の選択肢が広がり、より円滑で安全な医療の実現が期待されます。 フィブリンシーラントの使用は、科学技術の発展によって今後ますます進化し、改善されることでしょう。それにより、より多くの患者に対して有益な治療法が提供されることを願っています。 |
